［1］Christos Tapeinos, Matteo Battaglini, Gianni Ciofani.Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases[J].Control Release,2017, 264:306-332.

［2］Rainer H MuÈller, Karsten MaÈder, Sven Gohla. Solid lipid nanoparticles (SLN) for controlled drugdelivery-a review of the state of the art[J].European J Pharmaceutics and Biopharmaceutics, 2000, 50(1): 161-177.

［3］Peng Ji, Tong Yu, Ying Liu,et al. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics[J]. Drug Des Devel Ther, 2016, 10(1):911-925.

［4］Paolo Blasi,Aur´elieSchoubben,Giovanna ValentinaRomano,et al. Lipid nanoparticles for brain targeting II technological characterization[J]. Colloids and Surfaces B: Biointerfaces, 2013, 110:130-137.

［5］Paolo Blasi, Stefano Giovagnoli, Aurélie Schoubben,et al. Solid lipid nanoparticles fortargeted brain drug delivery[J]. Adv Drug Deliv Rev, 2007, 59(6):454-477.

［6］Donatella Paolino, Donato Cosco, Roberto Molinaro,et al. Supramolecular devices to improve the treatment of brain diseases[J].Drug Discov Today, 2011, 16(7-8): 311-324.

［7］Giovanni Tosi, Luca Costantino, Barbara Ruozi,et al. Polymeric nanoparticles for the drug delivery to the central nervous system[J].Expert Opin Drug Deliv, 2008, 5(2): 155-174.

［8］IvanaCacciatore, MicheleCiulla, ErikaFornasari,et al. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases[J].Expert Opin Drug Deliv,2016, 13(8): 1121- 1131.

［9］GregoryMarslin, KarthikSiram, XiangLiu,et al. Solid lipid nanoparticles of albendazole for enhancing cellular uptake and cytotoxicity against U-87 MG glioma cell lines[J].Molecules,2017, 22(11):2040.

［10］MalgorzataGeszke-Moritz, MichalMoritz. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies[J].Mater Sci Eng C Mater Biol Appl,2016, 68: 982-994.

［11］王婧雯,汤海峰.齐墩果酸固体脂质纳米粒的制备与质量评价[J]．第四军医大学学报, 2007, 28(5): 472-474．

［12］张卿,张良珂,袁佩,等.和厚朴酚固体脂质纳米粒的制备及性质研究[J].中草药, 2011, 42(4): 691-693.

［13］杨金枝,孙文霞,王姣姣,等.白杨素固体脂质纳米粒的制备及其药动学行为[J].中成药, 2018, 40(1): 76-80.

［14］Min Ji, Xiao-yuan Chen, Chien M Wai,et al. Synthensizing and dispersin silver nanoparticles in a water-in-supercritical carbon dioxide micromulsion[J]．Am Chem Soc, 1999, 121(11): 2631-2632．

［15］胡英,陈海靓,梁文权.槲皮素自乳化释药系统的制备和质量评价[J].中国中药杂志, 2007, 32(9): 805-807.

［16］张伟玲,刘晓娟.槲皮素自微乳制剂的制备[J].山东大学学报:医学版, 2016, 54(3): 41-44.

［17］厉英超,董蕾.高压乳匀法制备中药固体脂质纳米粒[J]．南方医科大学学报, 2006, 26(5): 541-544.

［18］陈克玲,郑瑞芳,姜雯.复方一枝蒿提取物固体脂质纳米粒的制备[J].中成药, 2018, 40 (9): 1949-1953.

［19］何瑶,郭晓华.依托泊苷固体脂质纳米粒的制备与抗癌活性研究[J].中国药师, 2018, 21(5): 792-796.

［20］AlamZeb, Omer SQureshi, Hoo-SeongKim,et al. High payload itra- conazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration[J].J Pharm Pharmacol,2017, 69(8): 955-966.

［21］孙陶利,戴智,蒋鹏程,等.阿魏酸川芎嗪固体脂质纳米粒制备及处方工艺优化[J].长沙医学院学报, 2018, 16(1): 7-11.

［22］VivekMakwana, Rashmi Jain, Komal Patel,et al. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach[J]. Int J Pharm, 2015, 495(1): 439-446.

［23］Melike Uner, Gülgün Yener. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives[J].Int J Nanomedicine, 2007, 2:289-300.

［24］Sylvia A Wissing, Oliver Kayser, Rainer Helmut Müller. Solid lipid nanoparticles for parenteral drug delivery[J].Adv Drug Deliv Rev, 2004, 56 :1257-1272.

［25］Gian Paolo Zara, Alessandro Bargoni, Roberta Cavalli,et al. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats[J].J Pharm Sci, 2002, 91:1324-1333.

［26］Yang-chao Luo, Zi Teng, Ying Li,et al. Solid lipid nanoparticles for oral drug delivery: Chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake[J].Carbohydr Polym, 2015, 122: 221-229．

［27］Carmelo Puglia, Paolo Blasi, Luisa Rizza,et al. Lipid nanoparticles for prolonged topical delivery: anin vitroandin vivoinvestigation[J].Int J Pharm, 2008, 357: 295-304.

［28］Roberta Cavalli, M Rosa Gasco, Patrizia Chetoni,et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin[J].Int J Pharm,2002, 238: 241-245.

［29］Slavomira Doktorovová, Andjelka B Kova?evi?, Maria L Garcia,et al. Preclinical safety of solid lipidnanoparticles and nanostructured lipid carriers: current evidence fromin vitroandin vivoevaluation[J].Eur J Pharm. Biopharm, 2016, 108: 235-252.

［30］杨时成,朱家壁,梁秉文,等.喜树碱固体脂质纳米粒的研究[J].药学学报, 1999, 34(2): 146-150.

［31］João F Pinto. Preparation of administrated solid lipid nanoparticles using pellets as carrier[J]. Pharmazie, 1999, 54(7): 5-12.

［32］Sabrina Weber, Andreas Zimmer, Jana Pardeike. Solid lipid nanoparticles (SLN) and nanostructuredlipid carriers (NLC) for pulmonary application: a review of the state of theart[J].Eur J Pharm Biopharm, 2014, 86: 7-22.

［33］梅之南,杨祥良,杨亚江,等.雷公藤内酯醇固体脂质纳米粒经皮渗透及抗炎活性的研究[J].中国药学杂志, 2003, 38(11):38.

［34］Roberta Cavalli, M Rosa Gasco, Patrizia Chetoni,et al. Solid lipidnanoparticles (SLN) as ocular delivery system fortobramycin[J]. Int J Pharm, 2002, 238(1-2): 241-245

［35］崔正云,刘彬,姜成哲,等.固体脂质纳米粒作为核酸疫苗载体的效应研究[J].东北农业大学学报, 2015, 46(8):15-20.

［36］Nina Pedersen, Susan Hansen, Annette V Heydenreich,et al. Solid lipid nanparticles can effectively bind DNA, streptavidin and biotinylated ligands[J]. Eur J Pharm Biopharm, 2006, 62(2): 155-162.

［37］Neda Naseri, Hadi Valizadeh, Parvin Zakeri-Milani. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application[J]. Adv Pharm Bull, 2015, 5: 305-313.

［38］Stefan Wilhelm, Anthony J Tavares, Qin Dai,et al. Analysis of nanoparticle delivery to tumours[J]. Nat Rev Mater, 2016, 1(5): 16014.

［39］Jinjin Shi, Philip W Kantoff, Richard Wooster,et al. Cancer nanomedicine: progress, challenges and opportunities[J].Nat Rev Cancer, 2016, 17: 20-37.

［40］Ashwath Jayagopal, MacRae F Linton, Sergio Fazio,et al. Insights into atherosclerosis using nanotechnology[J].Curr Atheroscler Rep, 2010, 12: 209-215.

［41］Mark E Lobatto, Valentin Fuster, Zahi A Fayad,et al. Perspectives and opportunities for nanomedicine in the management of atherosclerosis[J].Nat Rev Drug Discov, 2011, 10: 835-852.

［42］Jennifer Sargent. Cardiovascular disease: New nanomedicines for treating atherosclero ticplaques[J].Nat Rev Endocrinol, 2015, 11: 256-256.

［43］Xinlin Yang, Li Jin, Lu Yao,et al.Antioxidative nanofullerol prevents intervertebral disk degeneration[J]. Int J Nanomedicine, 2014, 9(1):2419-2430.

［44］Li Jin, Meng-meng Ding,Azra Oklopcic,et al. Nanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides[J].Nanomedicine, 2017, 13: 2049-2059.

［45］Tal Dvir, Michael Bauer, Avi Schroeder,et al. Nanoparticles targeting the infarcted heart[J].Nano Lett, 2011, 11: 4411-4414.

［46］Sophia Suarez, Adah Almutairi, Karen L Christman. Micro- and nanoparticles for treating cardiovascular disease[J].Biomater Sci, 2015, 3:564-580.

［47］Goo Yoon, Woo Park, In-Soo Yoon. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery[J]. Pharm Investig, 2013, 43(5): 353-362.